Literature DB >> 7858862

Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro.

S Greber1, C Schwarzer, G Sperk.   

Abstract

1. We investigated the effects of neuropeptide Y (NPY), peptide YY (PYY), NPY13-36, NPY18-36, [Leu31][Pro34]NPY and of pancreatic polypeptide Y (PPY) on calcium-dependent, potassium-stimulated glutamate release in superfused rat hippocampal slices. 2. NPY, PYY and the Y2 receptor agonist NPY13-36 equipotently inhibited the release of glutamate. The half-maximal response was observed at about 10 nM in a dose-dependent manner (3 to 100 nM). Maximal inhibition of 50 to 60% was obtained at 100 nM. At higher concentrations of the peptides (300 nM and 1 microM) this inhibition was partially or entirely reversed. Porcine NPY13-36 and NPY18-36 inhibited glutamate release by about 44% at 100 nM. 3. The specific Y1 receptor agonist, [Leu31][Pro34]NPY, caused an insignificant increase in glutamate release at 100 to 300 nM concentrations. PPY had no effect on potassium-evoked glutamate release in hippocampal slices at concentrations of 30 nM to 1 microM. 4. The experiments support previous electrophysiological data. They suggest a potent inhibitory action of NPY through NPY-Y2 receptors on the release of the excitatory amino acid glutamate in rat hippocampus. Especially under conditions of increased NPY synthesis, such as in epilepsy, this mechanism may be of pathophysiological relevance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858862      PMCID: PMC1510458          DOI: 10.1111/j.1476-5381.1994.tb17055.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Mechanism of presynaptic inhibition by neuropeptide Y at sympathetic nerve terminals.

Authors:  P T Toth; V P Bindokas; D Bleakman; W F Colmers; R J Miller
Journal:  Nature       Date:  1993-08-12       Impact factor: 49.962

2.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

3.  Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides.

Authors:  C Wahlestedt; N Yanaihara; R Håkanson
Journal:  Regul Pept       Date:  1986-02

4.  [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist.

Authors:  J Fuhlendorff; U Gether; L Aakerlund; N Langeland-Johansen; H Thøgersen; S G Melberg; U B Olsen; O Thastrup; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro.

Authors:  G J Klapstein; W F Colmers
Journal:  Hippocampus       Date:  1993-01       Impact factor: 3.899

6.  Neuropeptide Y innervation of the hippocampal region in the rat and monkey brain.

Authors:  C Köhler; L Eriksson; S Davies; V Chan-Palay
Journal:  J Comp Neurol       Date:  1986-02-15       Impact factor: 3.215

7.  [Leu31-Pro34] neuropeptide Y identifies a subtype of 125I-labeled peptide YY binding sites in the rat brain.

Authors:  D R Gehlert; S L Gackenheimer; D A Schober
Journal:  Neurochem Int       Date:  1992-07       Impact factor: 3.921

8.  Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat.

Authors:  M Heilig; R Murison
Journal:  Regul Pept       Date:  1987-11

9.  Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat.

Authors:  G Sperk; J Marksteiner; B Gruber; R Bellmann; M Mahata; M Ortler
Journal:  Neuroscience       Date:  1992-10       Impact factor: 3.590

10.  Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain.

Authors:  C Stenfors; E Theodorsson; A A Mathé
Journal:  J Neurosci Res       Date:  1989-11       Impact factor: 4.164

View more
  33 in total

Review 1.  Presynaptic modulation controlling neuronal excitability and epileptogenesis: role of kainate, adenosine and neuropeptide Y receptors.

Authors:  João O Malva; Ana P Silva; Rodrigo A Cunha
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

Review 2.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

3.  Neuropeptide Y and Y1 receptors in kindling epileptogenesis.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

4.  Gene therapy in epilepsy.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

Review 5.  Anxiety, Depression, and the Microbiome: A Role for Gut Peptides.

Authors:  Gilliard Lach; Harriet Schellekens; Timothy G Dinan; John F Cryan
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

6.  NPY2 Receptors Reduce Tonic Action Potential-Independent GABAB Currents in the Basolateral Amygdala.

Authors:  James P Mackay; Maria Bompolaki; M Regina DeJoseph; Sheldon D Michaelson; Janice H Urban; William F Colmers
Journal:  J Neurosci       Date:  2019-04-10       Impact factor: 6.167

Review 7.  Neuropeptide Y: potential role in recurrent developmental seizures.

Authors:  Celine Dubé
Journal:  Peptides       Date:  2006-12-29       Impact factor: 3.750

8.  Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo.

Authors:  S Foti; R P Haberman; R J Samulski; T J McCown
Journal:  Gene Ther       Date:  2007-08-23       Impact factor: 5.250

Review 9.  Ligands of the neuropeptide Y Y2 receptor.

Authors:  Gopi Kumar Mittapalli; Edward Roberts
Journal:  Bioorg Med Chem Lett       Date:  2013-12-04       Impact factor: 2.823

10.  Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression.

Authors:  K Obrietan; A N van den Pol
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.